Osteopathic treatment approach in somatoform disorders through bifocal integration- a randomized controlled trial

Not Applicable

Recruiting

Conditions: F45
Somatoform disorders

Registration Number: DRKS00031377

Lead Sponsor: Osteopathie Schule Deutschland

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 92

Inclusion Criteria

Age 18+
-Somatoform disorders according to the
Health Questionnaire PHQ-15,
from mild to moderate to severe somatization
- Physical complaints that have existed for at least 4 weeks and can remain in the supine position for at least 75 minutes
-Accessibility of the rooms in the
Osteopathy School Germany

Exclusion Criteria

-Acute serious illnesses or injuries such as fractures
- dominant systemic diseases requiring primary treatment
- Existing pregnancy
- further osteopathic interventions two weeks before and during the study period
- No mastery of the German language, whether spoken or written
-ongoing pension proceedings or pension that has already occurred due to
somatoform disorder
- Cardiovascular diseases such as cardiac arrhythmia
(extrasystoles, atrial fibrillation)
-No declaration of consent
-mental illnesses, due to which a psycho-therapeutic treatment takes place

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Test persons are asked about their well-being by means of questionnaires. The physical symptoms are measured with the Public health questionnaire (PHQ-15) and the quality of life with the Short Form health 36 (SF-36) questionnaire.<br>Data collection takes place before and after the first treatment, after the third treatment and as a follow-up, 3 months after the last treatment.

Secondary Outcome Measures

Name	Time	Method
The activity of the autonomic nervous system is evaluated by measuring the heart rate variability. Data collection takes place before and after the first treatment, after the third treatment and as a follow-up, 3 months after the last treatment.